✦ LIBER ✦

Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial

✍ Scribed by I. Jon Russell; A. Thomas Perkins; Joel E. Michalek; Oxybate SXB-26 Fibromyalgia Syndrome Study Group

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 127 KB
Volume: 60
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.24142

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gabapentin in the treatment of fibromyal

Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial

✍ Lesley M. Arnold; Don L. Goldenberg; Sharon B. Stanford; Justine K. Lalonde; H. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 2 views

## Abstract ## Objective To assess the efficacy and safety of gabapentin in patients with fibromyalgia. ## Methods A 12‐week, randomized, double‐blind study was designed to compare gabapentin (1,200–2,400 mg/day) (n = 75 patients) with placebo (n = 75 patients) for efficacy and safety in treatin

Etanercept in Sjögren's syndrome: A twel

Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial

✍ Vidya Sankar; Michael T. Brennan; Marc R. Kok; Rose Anne Leakan; Janine A. Smith 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

## Abstract ## Objective To assess the safety and potential efficacy of etanercept in the treatment of Sjögren's syndrome (SS). ## Methods This pilot study was a 12‐week randomized, double‐blind, placebo‐controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of e

The relationship of serum infliximab con

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

✍ E. William St.Clair; Carrie L. Wagner; Adedigbo A. Fasanmade; Benjamin Wang; Tho 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 1 views

## Abstract ## Objective To investigate the relationship between serum concentrations of infliximab, a monoclonal anti–tumor necrosis factor α antibody, and clinical improvement from infliximab therapy for rheumatoid arthritis (RA). ## Methods Multiple blood samples were obtained from each of 42

Evaluation of the efficacy and safety of

Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

✍ Oliver Distler; Wolfgang Eich; Eva Dokoupilova; Zdenek Dvorak; Martin Fleck; Mar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Denosumab treatment effects on structura

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

✍ Stanley B. Cohen; Robin K. Dore; Nancy E. Lane; Peter A. Ory; Charles G. Peterfy 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB 👁 1 views

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 1 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal